X linked adrenoleukodystrophy: Clinical presentation, diagnosis, and therapy

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 1, 1997, Pages 4-14

  Van Geel, Björn M ^a   Assies, Johanna ^b   Wanders, Ronald J A ^a   Barth, Peter G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Departments of Psychiatry and Internal Medicine

Author keywords

Adrenoleukodystrophy; Adrenomyeloneuropathy; Peroxisome; Very long chain fatty acids

Indexed keywords

BETA INTERFERON; CORTICOTROPIN; CYCLOPHOSPHAMIDE; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LORENZO OIL; PREDNISONE; VERY LONG CHAIN FATTY ACID;

ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; ADRENOLEUKODYSTROPHY; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; DEMYELINATION; DIET THERAPY; DISORDERS OF PEROXISOMAL FUNCTIONS; HEMIZYGOTE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; ONSET AGE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; TESTIS DISEASE; X CHROMOSOME LINKAGE;

EID: 0030751530     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.1.4     Document Type: Review

References (139)

1. Siemerling E, Creutzfeldt HG. Bronzekrankheit und sclerosierende Encephalomyelitis (Diffuse Sklerose). Archiv für Psychiatrie 1923;68:217-44.
2. Fanconi A, Prader A, Isler W, Luthy F, Siebenmann R. Morbus Addison mit X-chromosomaler Vererbung. Helvetica Paediatrica Acta 1963;18:480-501.
3. Blaw ME. Melanodermic type leukodystrophy (adrenoleukodystrophy). In: Vinken PJ, et al. Handbook of clinical neurology. Vol 10. New York: American Elsevier, 1970:128-33.
4. Budka H, Sluga E, Heiss WD. Spastic paraplegia associated with Addison's disease: adult variant of adrenoleukodystrophy. J Neurol 1976;213:237-50.
5. Moser HW, Smith KD, Moser AB. X-linked adrenoleukodystrophy. In: Scriver CR, et al. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995: 2325-49.
6. O'Neill BP, Marmion LC, Feringa ER. The adrenoleukomyeloneuropathy complex: expression in four generations. Neurology 1981;31:151-6.
7. Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K. Farcy acid abnormality in adrenoleukodystrophy. J Nsurochem 1976;26:851-60.
8. Johnson AB, Schaumburg HH, Powers JM. Histochemical characteristics of the striated inclusions of adrenoleukodystrophy. J Histochem Cytochem 1976;24:725-30.
9. Moser HW, Moser AB, Kawamura N, et al. Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol 1980;7:542-9.
10. Moser HW, Moser AB, Frayer KK, et al. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981;31:1241-6.
11. Singh I, Moser AE, Goldfischer S, Moser HW. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci USA 1984;81:4203-7.
12. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA 1988;85:7647-51.
13. Wanders RJA, van Roermund CWT, van Wijland MJA, et al. X-linked adrenoleukodys trophy: defective peroxisomal oxidation of very long chain fatty acids but not of very long chain fatty acyl-CoA esters. Clin Chim Acta 1987;165:321-9.
14. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA. Adrenoleukodystrophy: evidence for X-linkage, inactivation and selection favouring the mutant allele in heterozygous cells. Proc Natl Acad Sci USA 1981;78:5066-70.
15. Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726-30.
16. van Geel BM, Assies J, Weverling GJ, Barth PG. Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in the Netherlands: a survey of 30 kindreds. Neurology 1994;44:2343-6.
17. Sereni C, Paturneau-Jouas M, Aubourg P, Baumann N, Feingold J. Adrenoleukodystrophy in France: an epidemiological study. Neuroepidemiology 1993;12:229-33.
18. Costakos D, Abramson R, Edwards JG, Rizzo WB, Best RG. Attitudes toward presympcomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families. Am J Med Genet 1991;41:295-300.
19. Odone A, Odone M. Lorenzo's oil: a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989;5:55-61.
20. Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 1995;18:398-112.
21. Moser HW. Gene therapy in neurology. Eur Neurol 1994;34: 241-2.
22. Leiden JM. Gene therapy - promise, pittfalls and prognosis. N Engl J Med 1995;333:871-3.
23. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9.
24. Aubourg P, Chaussain JL. Adrenoleukodystrophy presenting as Addison's disease in children and adults. Trends Endocrinol Metab 1991;2:49-52.
25. van Geel BM, Assies J, Haverkort EB, et al. Delay in diagnosis of X-linked adrenoleukodystrophy. Clin Neurol Neurosurg 1993;95:115-20.
26. Moser HW, Bergin A, Naidu S, Ladenson PW. Adrenoleukodystrophy. Endocrinol Metab Clin North Am 1991;20: 297-317.
27. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol 1975;32:577-91.
28. Powers JM. Adreno-leukodystrophy (adreno-testiculoleuko-myelo-neuropathic-complex). Clin Neuropathol 1985;4:181-99.
29. Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. Am J Neuroradiol 1994;15:1761-6.
30. Powers JM, Schaumburg HH, Gaffney CL. Kluver-Bucy syndrome caused by adreno-leukodystrophy. Neurology 1980;30:1131-2.
31. James ACD, Kaplan P, Lees A, Bradley JJ. Schizophreniform psychosis and adrenomyeloneuropathy. J R Soc Med 1984;77:882-1.
32. Esiri MM, Hyman NM, Horton WL, Lindenbaum RH. Adrenoleukodystrophy: clinical, pathological and biochemical findings in two brothers with the onset of cerebral disease in adult life. Neuropathol Appl Neurobiol 1984;10: 429-45.
33. Sereni C, Ruel M, Iba-Zizen T, Baumann N, Marteau R, Paturneau-Jouas M. Adult adrenoleukodystrophy: a sporadic case? J Neurol Sci 1987;80:121-8.
34. Angus B, de Silva R, Davidson R, Bone I. A family with adult-onset cerebral adrenoleucodystrophy. J Neurol 1994; 241:497-9.
35. Farrell DF, Hamilton SR, Knauss TA, Sanocki E, Deeb SS. X-linked adrenoleukodystrophy: adult cerebral variant. Neurology 1993;43:1518-22.
36. Moser HW, Moser AB, Smith KD, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 1992;15:645-4.
37. Schaumburg HH, Powers JM, Raine CS, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. Neurology 1977;27:1114-9.
38. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. Brain MRI and electrophysiologic abnormalities in pre-clinical and clinical adrenomyeloneuropathy. Neurology 1992;42:85-91.
39. Kumar AJ, Kohler W, Kruse B, et al. MR findings in adult-onset adrenoleukodystrophy. Am J Neuroradiol 1995;16: 1227-37.
40. van Geel BM, Koelman JHTM, Barth PG, Ongerboer de Visser BW. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology 1996;46:112-8.
41. Chaudhry V, Moser HW, Cornblath DR. Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry 1996;61:181-5.
42. Maris T, Androulidakis EJ, Tzagournissakis M, Papavassiliou S, Moser H, Plaitakis A. X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis. Neurology 1994;45:1101-4.
43. Sadeghi-Nejad A, Senior B. Adrenomyeloneuropathy presenting as Addison's disease in childhood. N Engl J Med 1990;322:13-6.
44. Jorge P, Quelhas D, Oliveira P, Pinto R, Nogueira A. X-linked adrenoleukodystrophy in patients with idiopathic Addison disease. Eur J Pediatr 1994;153:594-7.
45. Schäfer JR, Ehlenz K, Steinmetz A, et al. Adrenomyeloneuropatie: eine haufige Ursache des Morbus Addison. Dtsch Med Wochenschr 1994;119:327-31.
46. Kong M, Jeffcoats J. Eighty-six cases of Addison's disease. Clin Endocrinol 1994;41:757-61.
47. Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996;81:470-4.
48. Aubourg P, Sellier N, Chaussain JL, Kalifa G. MRI detects cerebral involvement in neurologically asymptomatic patients with adrenoleukodystrophy. Neurology 1989;39: 1619-21.
49. Kruse B, Barker PB, van Zijl PCM, Duyn JH, Moonen CTW, Moser HW. Multislice proton magnetic resonance spectroscopy imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994;36:595-608.
50. Moser HW, Moser AB, Naidu S, Bergin A. Clinical aspects on adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:254-61.
51. Kuroda S, Hirano R, Yuasa S. Adrenoleukodystrophy-cerebello-brainstem dominant case. Acta Neuropathol 1983; 60:149-52.
52. Ohno T, Tsuchiya H, Fukuhara N, Yuasa T, Tsuji T, Miyatake T. Adrenoleukodystrophy: new clinical variant presenting as olivopontocerebellar atrophy. Ann Neurol 1983; 14:147-8.
53. Kobayashi T, Noda S, Umezaki H, et al. Familial spinocerebellar degeneration as an expression of adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 1986;49:1438-40.
54. Marsden CD, Obeso JA, Lang AE. Adrenomyeloneuropathy presenting as spinocerebellar degeneration. Neurology 1982;32:1031-2.
55. Weller M, Liedtke W, Petersen D, Opitz H, Poremba M. Very-late-onset adrenoleukodystrophy: possible precipitation of demyelination by cerebral contusion. Neurology 1992;42:367-70.
56. Wilkinson IA, Hopkins IJ, Pollard AC. Can head injury influence the site of demyelination in adrenoleukodystrophy? Dev Med Child Neurol 1987;29:797-800.
57. Powers JM, Schaumburg HH. A fatal cause of sexual inadequacy in men: adrenoleukodystrophy. J Urol 1980;124: 583-5.
58. Martin JJ, Dompas B, Ceuterick C, Jakobs K. Adrenomyeloneuropathy and adrenoleukodystrophy in two brothers. Eur Neurol 1980;19:281-7.
59. Ellington GM, Bateman DE, Jeffrey MJ, Lawton NF. Adrenoleukodystrophy: heterogeneity in two brothers. J Neurol Neurosurg Psychiatry 1989;52:310-3.
60. Dooley JM, Wright BA. Adrenoleukodystrophy mimicking multiple sclerosis. Can J Neurol Sci 1985;12:73-4.
61. Stöckler S, Millner M, Molzer B, Ebner F, Korner E, Moser HW. Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur Neurol 1993;33:390-2.
62. Pilz P, Schiener P. Kombination von morbus Addison und Morbus Schilder bei einer 43 jahrigen Frau. Arch Neuropathol 1973;26:357-60.
63. Schlote W, Molzer B, Peiffer J, et al. Adrenoleukodystrophy in an adult female. J Neurol 1987;235:1-9.
64. Simpson RHW, Rodda J, Reinecke CJ. Adrenoleukodystrophy in a mother and son. J Neurol Neurosurg Psychiatry 1987;50:1165-72.
65. Heffungs W, Hameister H, Ropers HH. Addison disease and cerebral sclerosis in an apparently heterozygous girl: evidence of inactivation of the adrenoleukodystrophy locus. Clin Genet 1980;18:184-8.
66. Dumic M, Gubarev N, Sikic N, Roscher A, Plavsic V, Filipovic-Grcic B. Sparse hair and multiple endocrine disorders in two women heterozygous for adrenoleukodystrophy. Am J Med Genet 1992;43:829-32.
67. Moser HW, Kok F, Neumann S, et al. Adrenoleukodystrophy update: genetics and effect of Lorenzo's oil therapy in asymptomatic patients. Int Pediatr 1994;9:196-204.
68. Hashmi M, Stanley W, Singh I. Lignoceroyl-CoASH ligase: enzyme defect in fatty acid β-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Lett 1986;196: 247-50.
69. Jakobs BS, Wanders RJA. Conclusive evidence that that very long chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts. Biochem Biophys Res Commun 1991;178:842-7.
70. de Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Physiol Rev 1966;46:323-57.
71. Hruban Z, Vigil EL, Slesers A, Hopkins E. Microbodies: constituent organelles of animal cells. Lab Invest 1972;27: 184-91.
72. Schutgens RBH, Barth PG, van Geel BM, Wanders RJA. Peroxisomal disorders: classification, diagnosis and treatment. In: Di Donato S, et al. Metabolic encephalopathies. London: John Libbey, 1995:129-40.
73. Wanders RJA, Heymans HSA, Schutgens RBH, Barth PG, van den Bosch H, Tager JM. Peroxisomal disorders in neurology. J Neurol Sci 1988;88:1-39.
74. Mosser J, Lutz Y, Stoeckel ME, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Molec Genet 1994;3:265-71.
75. Valle D, Gärtner J. Penetrating the peroxisome. Nature 1993;361:682-3.
76. Ligtenberg MJL, Kemp S, Sarde CO, et al. Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein. Am J Hum Genet 1995;56:44-50.
77. Kok F, Neumann S, Sarde C, et al. Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum Mutat 1995;6:104-15.
78. Krasemann EW, Meier V, Korenke GC, Hunneman D, Hanefeld F. Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. Hum Genet 1996;97:194-7.
79. Feigenbaum V, Lombard-Platet G, Guidoux S, Sarde C, Mandel J, Aubourg P. Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy. Am J Hum Genet 1996;58:1135-44.
80. Kemp S, Ligtenberg MJL, van Geel BM, et al. Identification of a two base pair deletion in five unrelated families with adrenoleukodystrophy: a possible hot spot for mutations. Biochem Biophys Res Commun 1994;202:647-53.
81. Maestri NE, Beaty TH. Predictions of a 2-locus model for disease heterogeneity: applications to adrenoleukodystrophy. Am J Med Genet 1992;44:576-82.
82. Sobue G, Ueno-Natsukari I, Okamoto H, et al. Phenotypic heterogeneity of an adult form of adrenoleukodystrophy in monozygotic twins. Ann Neurol 1994;36:912-5.
83. Korenke GC, Fuchs S, Krasemann E, et al. Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann Neurol 1996;40:254-7.
84. Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked Schilder disease): a pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol 1974;76:481-500.
85. Powers JM, Schaumburg HH. The testis in adrenoleukodystrophy. Am J Pathol 1981;102:90-8.
86. Griffin DE, Moser HW, Mendoza Q, Moench TR, O'Toole S, Moser AB. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 1985;18:660-4.
87. Whitcomb RW, Linehan WM, Knazek RA. Effect of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vivo. J Clin Invest 1988;81:185-8.
88. Phillips JP, Lockman LA, Shapiro EG, et al. CSF findings in adrenoleukodystrophy: correlation between measures of cytokines, IgG production, and disease severity. Pediatr Res 1994;10:289-94.
89. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-13.
90. Tonshoff B, Lehnert W, Ropers HH. Adrenoleukodystrophy: diagnosis and carrier detection by determination of long-chain fatty acids in cultured fibroblasts. Clin Genet 1982;22:25-9.
91. Tsuji S, Suzuki M, Ariga T, Sekine M, Kuriyama M, Miyatake T. Abnormality of long-chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy. J Neurochem 1981;36:1046-9.
92. Molzer B, Bernheimer H, Toifl K. Fatty acid patterns in brain, fibroblast, leukocyte and body fluid lipids in adrenoleukodystrophy. Acta Neuropathol 1981;(suppl VII):211-4.
93. Notarangelo LD, Parolini O, Baiguini G, et al. Carrier detection in X-linked adrenoleukodystrophy by determination of very long chain fatty acids and by linkage analysis. Eur J Pediatr 1992;151:761-3.
94. van Oost BA, van Zandvoort PM, Tunte W, et al. Linkage analysis in X-linked adrenoleukodystrophy and application in post- and prenatal diagnosis. Hum Genet 1991;86:404-7.
95. Boué J, Oberle I, Heilig R, et al. First trimester prenatal diagnosis of adrenoleukodystrophy by determination of very long chain fatty acids and by linkage analysis to a DNA probe. Hum Genet 1985;69:272-1.
96. Watkins PA, Gould SJ, Smith MA, et al. Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 1995;57:292-301.
97. Kemp S, Mooyer PAW, Bolhuis PA, et al. ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy. J Inherit Metab Dis 1996;19:667-74.
98. Wanders RJA, van Roermund CWT, Lageweg W, et al. X-linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect. J Inherit Metab Dis 1992;15:634-14.
99. Kennedy CR, Allen JT, Fensom AH, Steinberg SJ, Wilson R. X-linked adrenoleukodystrophy with non-diagnostic plasma very long chain fatty acids. J Neurol Neurosurg Psychiatry 1994;57:759-61.
100. Moser HW, Moser AE, Trojak JE, Supplee SW. Identification of female carriers of adrenoleukodystrophy. J Pediatr 1983;103:54-9.
101. Moser HW, Moser AB, Powers JM, et al. The prenatal diagnosis of adrenoleukodystrophy: demonstration of increased hexacosanoic acid concentrations in cultured amniocytes and fetal adrenal gland. Pediatr Res 1982;16: 172-5.
102. Wanders RJA, Schutgens RBH, van den Bosch H, Tager JM, Kleijer WJ. Prenatal diagnosis of inborn errors in peroxisomal β-oxidation. Prenat Diagn 1991;11:253-61.
103. Carey WF, Poulos A, Sharp P, et al. Pitfalls in the prenatal diagnosis of peroxisomal β-oxidation defects by chorionic villus sampling. Prenat Diagn 1994;14:813-819.
104. Gray RGF, Green A, Cole T, et al. A misdiagnosis of X-linked adrenoleucodystrophy in cultured chorionic villus cells by the measurement of very long chain fatty acids. Prenat Diagn 1995;15:486-90.
105. Imamura A, Suzuki Y, Song X, et al. Prenatal diagnosis of adrenoleukodystrophy by means of mutation analysis. Prenat Diagn 1996;16:259-61.
106. Wanders RJA, Schutgens RBH, Barth PG, Tager JM, van den Bosch H. Postnatal diagnosis of peroxisomal disorders: a biochemical approach. Biochimie 1993;75:269-79.
107. Blevins LS, Shankroff J, Moser HW, Ladenson PW. Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy. J Clin Endocrinol Metab 1994;78: 261-5.
108. Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante B, Fenselau C. Evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem Biophys Res Commun 1980;96:69-76.
109. Brown III FR, van Duyn MA, Moser AB, et al. Adrenoleukodystrophy: effects of of dietary restriction and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982;151: 164-72.
110. Tsuji S, Sano T, Ariga T, Miyatake T. Increased synthesis of hexacosanoic acid (C26:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J Biochem 1981;90: 1233-6.
111. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy: oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 1986;36: 357-61.
112. Rizzo WB, Phillips MW, Dammann AL, et al. Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21:232-9.
113. Moser AB, Borel J, Odone A, et al. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol 1987;21:240-9.
114. Rizzo WB, Leshner RT, Odone A, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22.
115. Asano J, Suzuki Y, Yajima S, et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994;16:454-8.
116. Korenke GC, Hunneman DH, Kohler J, Stöckler S, Landmark K, Hanefeld R Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 1995;154:64-70.
117. Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6.
118. Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res 1994;8:1073-82.
119. Moser HW. Adrenoleukodystrophy: natural history, treatment and outcome. J Inherit Metab Dis 1995;18:435-17.
120. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids (Lorenzo's oil) as treatment for adrenomyeloneuropathy. N Engl J Med 1993; 329:745-52.
121. Assies J, van Geel BM, Weverling GJ, Haverkort EB, Barth PG. Endocrine evaluation during dietary therapy for adrenomyeloneuropathy. In: Bhatt HR, et al, Advances in Thomas Addison's diseases, vol 1. Bristol: Journal of Endocrinology, 1994:191-8.
122. Zierz S, Schröder R, Unkrig CJ. Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy. Clin Invest 1993;71:802-5.?
123. Stöckler S, Molzer B, Plecko B, et al. Giant platelets in erucic acid therapy for adrenoleukodystrophy. N Engl J Med 1993;341:1414-5.
124. Toplak H, Wascher TC, Pleschko B, et al. Reduced stimulability of platelet surface adhesion molecules under treatment with Lorenzo's oli. J Inherit Metab Dis 1994;17: 628-9.
125. Zinkham WH, Kickler T, Borel J, Moser HW. Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy. N Engl J Med 1993;328:1126-7.
126. Bernheimer H, Budka H, Muller P. Brain tissue immunoglobulins in adrenoleukodystrophy: a comparison with multiple sclerosis and systemic lupus erythematosus. Acta Neuropathol 1983;59:95-102.
127. Moser HW, Tutschka PJ, Brown III FR, et al. Bone marrow transplant in adrenoleukodystrophy. Neurology 1984;34: 1410-7.
128. Aubourg P, Blanche S, Jambaqué I, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:1860-6.
129. Loes DJ, Stillman AE, Hite S, et al. Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. Am J Neuroradiol 1994;15:1767-71.
130. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-29.
131. Murphy JV, Marquardt KM, Moser HW, van Duijn MA. Treatment of adrenoleukodystrophy by diet and plasmapheresis. Ann Neurol 1982;12:220.
132. Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH. Adrenoleukodystrophy: failure of immunosuppression to prevent neurological progression. Arch Neurol 1981;38: 48-9.
133. Naidu S, Bresnan MJ, Griffin D, O'Too;e S, Moser HW. Childhood adrenoleukodystrophy: failure of intensive immunosuppression to arrest neurological progression. Arch Neurol 1988;45:846-8.
134. Miike T, Taku K, Tamura T, et al. Clinical improvement of adrenoleukodystrophy following intravenous gammaglobulin therapy. Brain Dev 1989;11:134-7.
135. Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 1994; 57(suppl):69-70.
136. Paty DW, Li DKB, the UBS MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
137. Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-5.
138. Korenke GC, Christen H, Hunneman DH, Hanefeld F. Failure of beta interferon therapy in X-linked adrenoleukodystrophy. Eur J Pediatr 1996;155:833.
139. Carder N, Lopez J, Moullier P, et al. Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci USA 1995;92:1674-8.